




## CV Template of KATRD International Conference 2021

<b>Name</b>	Alberto Papi			
<b>First Name</b>	Alberto	<b>Last Name</b>	Papi	
<b>Country</b>	Italy			
<b>Organization</b>	University of Ferrara			
<b>Current Position</b>	Full Professor of Respiratory Medicine			

### Educational Background

Degree in Medicine and Surgery, 110/110 summa cum laude, 1985 University of Ferrara, Italy  
Specialization in Respiratory Medicine, 70/70 summa cum laude, University of Parma, Italy

### Professional Experiences

Institute of Respiratory Diseases, University of Ferrara, Assistant Professor of Medicine, 1990-2001

University of Nebraska Medical Centre, School of Medicine, Pulmonary and Critical Care Medicine Section, Visiting Scientist, August 1990

University of Nebraska Medical Centre, School of Medicine, Pulmonary and Critical Care Medicine Section, Visiting Scientist, May 1991

Institute of Occupational Medicine, University of Padua, 1991-1992, Visiting Scientist

University Medicine, University of Southampton, Research Fellow, October 1994 - December 1997

University of Ferrara, Associate Professor of Respiratory Medicine, September 2001-2004

University of Ferrara  
Full Professor of Respiratory Medicine, Head Respiratory Medicine, November 2004-  
Deputy Head Department of Medical Science, November 2012-2017  
Vice-President School of Medicine, March 2014-2017

### Professional Organizations

Member of GOLD Science Committee 2107-  
Honorary Lecturer, University Medicine, University of Southampton (U.K.) 1998-  
Fellow of The European Respiratory Society (FERS) 2015-



## Main Scientific Publications

Total number of publications in PubMed: 430

H-Index: 78

Last year publications:

1. Zheng J, Baldi S, Zhao L, Li H, Lee KH, Singh D, Papi A, Grapin F, Guasconi A, Georges G. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. *Respir Res* 2021; 22: 90.
2. Williams TC, Jackson DJ, Maltby S, Walton RP, Ching YM, Glanville N, Singanayagam A, Brewins JJ, Clarke D, Hirsman AG, Loo SL, Wei L, Beale JE, Casolari P, Caramori G, Papi A, Belvisi M, Wark PAB, Johnston SL, Edwards MR, Bartlett NW. Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. *Am J Respir Cell Mol Biol* 2021; 64: 344-356.
3. Spadaro S, Fogagnolo A, Campo G, Zucchetti O, Verri M, Ottaviani I, Tunstall T, Grasso S, Scaramuzzo V, Murgolo F, Marangoni E, Vieceli Dalla Sega F, Fortini F, Pavasini R, Rizzo P, Ferrari R, Papi A, Volta CA, Contoli M. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. *Crit Care* 2021; 25: 74.
4. Papi A, Virchow JC, Singh D, Kots M, Vele A, Georges G, Canonica GW. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. *J Allergy Clin Immunol* 2021.
5. Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - A narrative review. *Eur J Intern Med* 2021; 85: 14-22.
6. Papi A, Di Stefano AFD, Radicioni M. Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. *Adv Ther* 2021; 38: 468-478.
7. Papi A, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Holliday M, Houghton C, Morandi L, Oldfield K, Pavord ID, Reddel HK, Williams M, Weatherall M, Beasley R, Novel SST. Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma. *Eur Respir J* 2021; 57.
8. Papi A, Beghe B, Fabbri LM. Rate of Decline of FEV1 as a Biomarker of Survival? *Am J Respir Crit Care Med* 2021; 203: 663-665.
9. Murray CS, Lucas SJ, Blakey J, Kaplan A, Papi A, Paton J, Phipatanakul W, Price D, Teoh OH, Thomas M, Turner S, Papadopoulos NG. A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care. *Eur Respir J* 2021.
10. Marcellini A, Swieboda D, Guedan A, Farrow SN, Casolari P, Contoli M, Johnston SL, Papi A, Solari R. Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication. *Eur J Pharmacol* 2021; 893: 173839.
11. Magnussen H, Lucas S, Lapperre T, Quint JK, Dandurand RJ, Roche N, Papi A, Price D, Miravittles M, Respiratory Effectiveness G. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. *Respir Res* 2021; 22: 25.
12. MacLeod M, Papi A, Contoli M, Beghe B, Celli BR, Wedzicha JA, Fabbri LM. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. *Respirology* 2021; 26: 532-551.
13. Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. *Lancet Respir Med* 2021; 9: 69-84.
14. Heffler E, Detoraki A, Contoli M, Papi A, Paoletti G, Malipiero G, Brussino L, Crimi C, Morrone D, Padovani M, Guida G, Gerli AG, Centanni S, Senna G, Paggiaro P, Blasi F, Canonica GW, Group SW. COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. *Allergy* 2021; 76: 887-892.
15. Heffler E, Detoraki A, Contoli M, Papi A, Paoletti G, Malipiero G, Brussino L, Crimi C, Morrone D, Padovani M, Guida G, Gerli AG, Centanni S, Senna G, Paggiaro P, Blasi F, Canonica GW, Group SW. Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes



- from COVID-19? *Allergy* 2021; 76: 961-962.
16. Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF. From GOLD 0 to Pre-COPD. *Am J Respir Crit Care Med* 2021; 203: 414-423.
  17. Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, Papi A, Stockley RA, Wedzicha J, Vogelmeier CF. Reply to: Thomson, to Neder et al., and to Wouters. *Am J Respir Crit Care Med* 2021.
  18. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2021; 203: 24-36.
  19. Di Marco F, D'Amato M, Lombardo FP, Micheletto C, Heiman F, Pegoraro V, Boarino S, Manna G, Mastromauro F, Spennato S, Papi A. The Burden of Short-Acting beta2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program. *Adv Ther* 2021.
  20. Delgado-Eckert E, James A, Meier-Girard D, Kupczyk M, Andersson LI, Bossios A, Mikus M, Ono J, Izuhara K, Middelveld R, Dahlen B, Gaga M, Siafakas NM, Papi A, Beghe B, Joos G, Rabe KF, Sterk PJ, Bel EH, Johnston SL, Chanez P, Gjomarkaj M, Howarth PH, Nizankowska-Mogilnicka E, Dahlen SE, Frey U. Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation. *J Allergy Clin Immunol* 2021.
  21. Cruz AA, Barile S, Nudo E, Brogelli L, Guller P, Papi A. ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy. *Asthma Res Pract* 2021; 7: 1.
  22. Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, Torsani F, Morandi L, Ronzoni L, Zucchetti O, Pavasini R, Fogagnolo A, Volta CA, Bartlett NW, Johnston SL, Spadaro S, Campo G. Blood Interferon-alpha Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients. *Front Immunol* 2021; 12: 648004.
  23. Canonica GW, Blasi F, Crimi N, Paggiaro P, Papi A, Fanelli F, Stassaldi A, Furneri G. Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. *Clin Mol Allergy* 2021; 19: 5.
  24. Campisi R, Crimi C, Nolasco S, Beghe B, Antonicelli L, Guarnieri G, Scichilone N, Porto M, Macchia L, Scioscia G, Foschino Barbaro MP, Papi A, Crimi N. Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. *J Asthma Allergy* 2021; 14: 575-583.
  25. Calverley P, Rogliani P, Papi A. Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. *Drug Saf* 2021; 44: 273-290.
  26. Brusselle G, Nicolini G, Santoro L, Guastalla D, Papi A. BDP/formoterol MART asthma exacerbation benefit increases with blood eosinophil level. *Eur Respir J* 2021.
  27. Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. *Allergy* 2021; 76: 269-280.
  28. Bansal S, Anderson M, Anzueto A, Brown N, Compton C, Corbridge TC, Erb D, Harvey C, Kaisermann MC, Kaye M, Lipson DA, Martin N, Zhu CQ, Papi A. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. *NPJ Prim Care Respir Med* 2021; 31: 29.
  29. Aris E, Harrington L, Bhavsar A, Simeone JC, Ramond A, Papi A, Vogelmeier CF, Meszaros K, Lambrelli D, Mukherjee P. Burden of Pertussis in COPD: A Retrospective Database Study in England. *COPD* 2021; 18: 157-169.
  30. Agusti A, Fabbri LM, Baraldi E, Celli B, Corradi M, Faner R, Martinez FD, Melen E, Papi A. Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. *Eur J Intern Med* 2021.
  31. Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernandez-Martin I, Knibb R, Makela M, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Perez de Llano L, Pfaar O, Quirce S, Sastre J, Shamji M, Schwarze J, Palomares O, Jutel M. EAACI Biologicals Guidelines-Recommendations for severe asthma. *Allergy* 2021; 76: 14-44.